114 related articles for article (PubMed ID: 28823264)
21. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M
J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837
[TBL] [Abstract][Full Text] [Related]
22. [Clinical features and prognostic factors of elderly patients with mantle cell lymphoma].
Hao XY; Yang P; Zhang W; Liu H; Sun XH; Xiao XB; Wang JW; Li ZL; Li LH; Wang SY; He J; Li XL; Jing HM
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):495-500. PubMed ID: 37550206
[No Abstract] [Full Text] [Related]
23. [Clinicopathologic features and prognosis of mantle cell lymphoma: an analysis of 349 cases].
Hou WH; Wei P; Xie JL; Zheng YY; Zhang YL; Zhou XG
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):417-422. PubMed ID: 29886584
[No Abstract] [Full Text] [Related]
24. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
[TBL] [Abstract][Full Text] [Related]
26. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
27. [Change of NK Cell Number in Peripheral Blood of Patients with Mantle Cell Lymphoma and Its Clinical Significance].
Han DL; Han YY; Bao YL; Zhao WX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):772-776. PubMed ID: 28641633
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.
Gressin R; Caulet-Maugendre S; Deconinck E; Tournilhac O; Gyan E; Moles MP; El Yamani A; Cornillon J; Rossi JF; Le Gouill S; Lepeu G; Damaj G; Celigny PS; Maisonneuve H; Corront B; Vilque JP; Casassus P; Lamy T; Colonna M; Colombat P;
Haematologica; 2010 Aug; 95(8):1350-7. PubMed ID: 20220059
[TBL] [Abstract][Full Text] [Related]
29. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma.
Spurgeon SE; Pindyck T; Okada C; Chen Y; Chen Z; Mater E; Abbi K; Epner EM
Leuk Lymphoma; 2011 Aug; 52(8):1488-94. PubMed ID: 21623691
[TBL] [Abstract][Full Text] [Related]
30. Mantle cell lymphoma epidemiology: a population-based study in France.
Leux C; Maynadié M; Troussard X; Cabrera Q; Herry A; Le Guyader-Peyrou S; Le Gouill S; Monnereau A
Ann Hematol; 2014 Aug; 93(8):1327-33. PubMed ID: 24763513
[TBL] [Abstract][Full Text] [Related]
31. Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma.
Kang BW; Sohn SK; Moon JH; Chae YS; Kim JG; Lee SJ; Kim WS; Lee JJ; Lee SR; Park KU; Lee HS; Lee WS; Won JH; Park MR; Kwak JY; Kim MK; Kim HJ; Oh SY; Kang HJ; Suh C
Blood Res; 2014 Mar; 49(1):15-21. PubMed ID: 24724062
[TBL] [Abstract][Full Text] [Related]
32. Conjunctival Lymphoma--An International Multicenter Retrospective Study.
Kirkegaard MM; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Toft PB; Vemuganti GK; Thuro BA; Curtin J; Heegaard S
JAMA Ophthalmol; 2016 Apr; 134(4):406-14. PubMed ID: 26891973
[TBL] [Abstract][Full Text] [Related]
33. Mantle cell lymphoma in the ocular adnexal region.
Looi A; Gascoyne RD; Chhanabhai M; Connors JM; Rootman J; White VA
Ophthalmology; 2005 Jan; 112(1):114-9. PubMed ID: 15629830
[TBL] [Abstract][Full Text] [Related]
34. [Relationship of Expression of Circ_cgga162 with the Prognosis of Patients with Mantle Cell Lymphoma].
Li Y; Jia ZW; Liu JX; Ye JW; Kong XY; Yang ZF; Liu XY; Luo JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):876-880. PubMed ID: 32552951
[TBL] [Abstract][Full Text] [Related]
35. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
[TBL] [Abstract][Full Text] [Related]
36. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
37. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Eskelund CW; Kolstad A; Jerkeman M; Räty R; Laurell A; Eloranta S; Smedby KE; Husby S; Pedersen LB; Andersen NS; Eriksson M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Workman CT; Garde C; Elonen E; Brown P; Grønbaek K; Geisler CH
Br J Haematol; 2016 Nov; 175(3):410-418. PubMed ID: 27378674
[TBL] [Abstract][Full Text] [Related]
38. [Mantle cell lymphoma: clinicopathologic features and prognostic factors of 102 cases occurring in Chinese patients].
Ji H; Li GD; Li FY; Bai YQ; Chen Y; Yang MZ; Wang LJ; Tang Y; Zhang P; Xia T; Li C; Feng J; Zou ZK; Yixi JC
Zhonghua Bing Li Xue Za Zhi; 2007 Nov; 36(11):730-5. PubMed ID: 18307875
[TBL] [Abstract][Full Text] [Related]
39. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
40. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
